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 ABSTRACT 
 
The overall aim of this thesis was to investigate the relation of homocysteine (tHcy), vitamin B12, 
and folate with Alzheimer’s disease (AD), cognitive performance, and structural brain changes in 
population-based studies of Finnish and Swedish elderly individuals. 
Study I. Serum levels of tHcy, holotranscobalamin (holoTC, the active fraction of vitamin B12), 
and folate were assessed in 274 individuals aged 65-79 years and without dementia from the 
Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study. Participants were followed-up 
for 7 years to detect incident AD. The odds ratios (OR) (95% confidence interval [CI]) for AD 
were 1.16 (1.04-1.31) for each increase of 1 μmol/L tHcy and 0.980 (0.965-9.995) for each 
increase of 1pmol/L holoTC. While adjusting for holoTC attenuated the tHcy-AD relation, the 
holoTC-AD link was less influence by controlling for tHcy. The protective effects of holoTC were 
more pronounced with increasing age. 
Study II. In the CAIDE study, performance in several cognitive domains was assessed on two 
occasions. Higher tHcy values among 65-79 years old persons were associated with worse 
performance on global cognition, episodic memory, executive functions and verbal expression 7 
years later. Elevated holoTC was related to better performance on global cognition, executive 
functions, and psychomotor speed. After excluding participants with incident dementia, tHcy and 
holoTC remained associated with several cognitive domains, and folate became associated with 
global cognition and verbal expression. The protective effects of holoTC were present over the 
whole normal range of holoTC. 
Study III. The associations of baseline plasma tHcy with neuropathological  and post-mortem 
magnetic resonance imaging (MRI) findings up to 10 years later were investigated in the Vantaa 
85+ study including individuals aged >85 years. tHcy levels in the highest quartile were related to 
about 2.5-fold increased OR for higher neurofibrillary tangles burden. This association was 
present particularly in subjects with dementia, cerebral infarcts, and with longer follow-up 
duration. tHcy tended to relate to amyloid -β accumulation in people with longer follow-up time. 
Higher tHcy levels were also associated with more severe medial temporal lobe atrophy and 
periventricular white matter hyperintensities on post-mortem MRI. 
Study IV. Plasma B12 and red blood cell folate were examined in relation to brain volumes in a 
Swedish population-based study (The Swedish National Study of Aging and Care in Kungsholmen 
(SNAC-K)), including dementia-free individuals aged >60 years with MRI scans at 2-3 occasions 
over 6 years. Higher baseline plasma B12 concentrations were associated with decreased rate of 
total brain tissue and grey matter volume loss, even in non-demented elderly. The protective 
effects of vitamin B12 were present over the whole distribution of vitamin B12 levels. 
Conclusions: Results of this project indicate that lower B12, elevated tHcy, and lower folate 
levels are involved in late-life cognitive impairment. Assessments of B12 and folate status 
(including functional indicators such as tHcy or holoTC) are recommendable in elderly at risk of 
dementia. Adequately timed and powered randomized controlled trials are needed to determine the 
impact of B-vitamin supplementation on preventing cognitive decline and dementia-related 
pathology. 
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